Skip to content
New platform coming soon — AI-Based Analysis with Human-Generated Insights
Stock Target Advisor Stock Target Advisor Market intelligence
  • Research
  • Market Analysis
  • Analyst Ratings
  • Top Stocks
  • Contact

Browse research

Author: Muzzammil Ahmad

Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product/services forecast as indicated by major brokers covering the stock.
Top Analyst Ratings & Analysis: Aug 7th
Market News & Insights Feb 16, 2024

Morgan Stanley Analyst Predicts Tesla Plunge but Long-term Boom

Investors and Wall Street analysts are still split down the middle over Tesla Inc. (TSLA: NSD) stock. Morgan Stanley’s Adam Jonas, an…

#Artificial Intelligence #Automotive #Earnings
Lululemon
Market News & Insights Feb 16, 2024

Lululemon’s Stock Price Drops: Time to Take Advantage?

Lululemon Athletica Inc (LULU: NSD) has seen a decline in its stock performance recently, with a decrease of over 10% from its…

#analyst ratings #Retail Stocks
Stellantis NV Stock Overview
Market News & Insights Feb 15, 2024

Stellantis NV: A Promising Investment Amidst Recent Challenges

Stellantis NV (STLA: NYE) has been hit by margin declines attributed to strikes and competitive pressures in North America. The disruptions have…

#Earnings
Warren Buffett Sells Apple, Buys Chevron Holdings
Market News & Insights Feb 15, 2024

Warren Buffett Sells Apple Stake, Buys Chevron Holdings

Warren Buffett’s Berkshire Hathaway disclosed substantial modifications to its investment portfolio in its most recent 13F filing. A notable investor has reduced…

#U.S. Markets
SAGE Therapeutics Faces Depression Drug Approval Delays
Market News & Insights Feb 15, 2024

SAGE Therapeutics Faces Depression Drug Approval Delays

SAGE Therapeutics Inc. (SAGE: NSD) has recently encountered unforeseen turbulence. A new risk has emerged and is adding pressure to the biotech…

#analyst ratings #Dividends #Earnings

Posts pagination

Previous 1 … 253 254 255 256 257 … 301 Next
Stock Target Advisor

Timely market news, analyst rating changes, and practical investment research for investors around the world.

  • Research
  • Analyst Ratings
  • Market Analysis
  • Top Stocks
  • About Us
  • Contact Us
  • Contribute a Post
© 2026 Stock Target Advisor. All rights reserved.